Skip to main content
. Author manuscript; available in PMC: 2014 Sep 25.
Published in final edited form as: J Carcinog Mutagen. 2014 May 31;5(3):1000176. doi: 10.4172/2157-2518.1000176

Table 1.

Overview of indications for approved targeted therapies against EGFR and HER-2.

Cancer Type EGFR expression HER-2 expression Approved Targeted Therapy
Breast Cancer Yes Yes Lapatinib, trastuzumab, pertuzumab, T-DM1
Colorectal Cancer Yes Yes Cetuximab, panitumumab
Gastric Cancer (GEJ) No Yes Trastuzumab
HNSCC Yes No Cetuximab
NSCLC Yes No Afatinib, Erlotinib, Gefitinib
Pancreatic Cancer Yes Yes Erlotinib